If you flush alteplase into the bloodstream instead of aspirating it from a catheter, you push a clot-dissolving drug directly into circulation. In most cases, the 2 mg dose used for catheter clearance is small enough that the body neutralizes it quickly, but flushing rather than aspirating bypasses a key safety step and can cause complications in certain patients.
The standard protocol exists for a reason: alteplase is meant to sit inside the catheter, dissolve the clot, and then be pulled back out along with the clot debris. Flushing it forward skips that removal step and sends both the drug and any loosened clot material into the bloodstream.
How the Drug Is Supposed to Work
Alteplase is a synthetic version of a protein your body naturally produces to break down blood clots. It works by converting a substance called plasminogen into plasmin, which chews through the fibrin mesh that holds clots together. This process is highly efficient on the surface of a clot but far less active in open blood. In fact, alteplase is roughly 100 times more effective when it’s in direct contact with fibrin than when it’s floating freely in plasma.
For catheter clearance, a dose of up to 2 mg in 2 mL of solution is instilled into the blocked lumen and left to dwell for 30 to 120 minutes. After the dwell time, the correct procedure is to attempt to aspirate blood. If the catheter is working again, 4 to 5 mL of blood should be withdrawn to remove the alteplase and any residual clot fragments. That aspirate gets discarded, and only then is the catheter flushed with normal saline.
What Flushing Does Differently
Flushing pushes the alteplase solution forward through the catheter tip and into the patient’s bloodstream. Two things enter circulation that shouldn’t: the drug itself and fragments of the clot it just dissolved.
The drug component is cleared rapidly. Alteplase has an initial half-life of less than 5 minutes, and the liver processes it at a rate of 380 to 570 mL per minute. A 2 mg catheter dose is a fraction of the 100 mg doses used to treat stroke or heart attack, so in a healthy patient the systemic effect is minimal. Free plasmin (the active enzyme alteplase creates) is also quickly deactivated by a natural inhibitor in the blood.
The clot fragments are a different concern. When alteplase breaks apart an occlusion, the debris is supposed to be pulled out by aspiration. Flushing can send those fragments downstream, where they could lodge in smaller vessels. Depending on the catheter’s location, this could mean fragments traveling toward the lungs or other organs. The risk of a clinically significant embolism from catheter-sized clot debris is low, but it’s the primary reason aspiration is the required technique.
When Flushing Poses a Real Danger
For certain patients, even a small amount of alteplase reaching the bloodstream creates meaningful risk. Clinical guidelines flag several conditions where this is a concern:
- Active internal bleeding: Alteplase impairs clot formation throughout the body, which can worsen existing hemorrhage.
- Recent surgery or delivery: Within 48 hours of surgery, childbirth, or deep tissue biopsy, surgical sites may not have formed stable clots yet.
- Low platelet counts or clotting disorders: Patients who already have trouble forming clots are more vulnerable to any additional clot-dissolving activity.
- Recent puncture of non-compressible vessels: Bleeding at sites where pressure can’t easily be applied is difficult to control.
- Severe liver or kidney disease: These conditions already impair the body’s ability to manage clotting, and they may also slow clearance of the drug.
In these patients, the adverse effects of systemic alteplase exposure mirror what can happen with full therapeutic doses: abnormal bleeding (from gums, urine, stool, or surgical sites), blood pressure drops, nausea, vomiting, or in rare cases, serious hemorrhage. Signs to watch for include blood in urine or stool, unexplained bruising, coughing up blood, or bleeding that won’t stop.
Why It Usually Doesn’t Cause Harm
In an otherwise healthy patient with no bleeding risk factors, an accidental flush of 2 mg alteplase is unlikely to cause a noticeable clinical event. The dose is tiny compared to therapeutic doses (which range from 50 to 100 mg for stroke and heart attack), the drug is inactivated within minutes, and the clot-dissolving enzyme it generates is rapidly neutralized in open blood. Most of the drug’s potency is spent on the fibrin clot inside the catheter during the dwell period, leaving less active drug to enter circulation.
That said, “unlikely to cause harm” is not the same as “correct technique.” Aspiration is the standard because it eliminates two avoidable risks at once: systemic drug exposure and clot embolization. If alteplase has already been flushed, monitoring for signs of bleeding or embolism is appropriate, especially in the first few hours. The drug’s short half-life means that any systemic effect will be brief, but clot fragments, once displaced, don’t resolve on the same timeline.